Belite Bio to Present Phase 3 Stargardt Disease Data at Euretina…

Event summary

Belite Bio will present Phase 3 DRAGON study results for tinlarebant in Stargardt disease at Euretina on October 4, 2026.
The company's NDA for tinlarebant was accepted by the FDA with priority review in August 2026, with a PDUFA date of February 12, 2027.
Tinlarebant has received multiple regulatory designations including Breakthrough Therapy and Orphan Drug status in the U.S. and Europe.
The therapy targets vitamin A-based toxins in the retina, addressing a currently untreated form of inherited macular dystrophy.

The big picture

Belite Bio's upcoming presentations mark a critical inflection point in the development of tinlarebant, a first-in-class oral therapy for Stargardt disease. The FDA's priority review designation underscores the unmet need in this rare retinal condition, while the Phase 3 data could set a new benchmark for treating inherited macular dystrophies. The company's ability to leverage these milestones will be key to its long-term valuation in the competitive ophthalmology space.

What we're watching

Regulatory Pathway: Whether the FDA's priority review will result in accelerated approval for tinlarebant in Stargardt disease.
Clinical Validation: How the Phase 3 DRAGON study results will position tinlarebant against potential competitors in retinal disease treatment.
Commercial Strategy: The pace at which Belite Bio can expand tinlarebant's indications beyond Stargardt disease into geographic atrophy.